Compounded Semaglutide & Tirzepatide Prices 2026: FDA Status & Current Pricing
Both semaglutide and tirzepatide have been removed from the FDA drug shortage list, ending the legal pathway that allowed mass-marketed compounding by 503B outsourcing facilities. Patient-specific compounding by 503A pharmacies remains legal under federal law. Compounded semaglutide currently runs $146–$299/month and compounded tirzepatide $258–$399/month through compliant 503A providers. The FDA has issued 50+ warning letters in 2025–2026, and access could continue to tighten.
If you've been researching compounded GLP-1 medications, you've probably noticed conflicting information about whether they're still legal, whether they're still available, and what they cost. The honest answer is: it's complicated, the regulatory environment is actively shifting, and pricing from compliant providers reflects that uncertainty. This guide explains exactly where things stand in April 2026 — what the FDA has done, what's still legal, and what you'll actually pay through providers operating within the current rules.
Current pricing from compliant providers
Let's start with what matters most to most people reading this — the actual prices from telehealth providers operating under the current 503A patient-specific compounding pathway. These are the verified 2026 cash-pay rates:
| Medication | Cheapest Intro | Typical Refill | 12-Month Range |
|---|---|---|---|
| Compounded semaglutide injection | $146/mo | $249–$299/mo | ~$1,752–$3,588 |
| Compounded semaglutide oral tablet | $249/mo | $299–$369/mo | ~$3,588–$4,428 |
| Compounded tirzepatide injection | $258/mo | $299–$399/mo | ~$3,588–$4,788 |
| Compounded tirzepatide oral tablet | $279/mo | $369–$399/mo | ~$4,428–$4,788 |
For context, brand-name Wegovy through NovoCare self-pay runs roughly $3,888/year, brand-name Zepbound through LillyDirect runs roughly $5,188/year, and the new Wegovy pill at NovoCare runs $2,788/year at the starter dose. Compounded semaglutide is meaningfully cheaper than every brand-name pathway except the Wegovy pill; compounded tirzepatide is cheaper than Zepbound at most dose tiers.
Synergy Rx operates through licensed 503A pharmacy partners with concierge-style provider care, frequent check-ins, and dose titration support. Mid-market pricing with higher-touch service than budget tier providers — useful for patients who want a more managed compounding pathway given the regulatory environment.
Check Synergy Rx Pricing →The FDA timeline: how we got here
Compounded GLP-1s exploded into the consumer market during the 2022–2024 shortages of Wegovy and Zepbound. When the shortages ended, a regulatory cascade reshaped the entire market. Here's the sequence that matters for understanding the current state:
503A vs 503B: the distinction that determines everything
The current regulatory picture hinges on a single distinction in federal pharmacy law. If you're evaluating a compounded GLP-1 provider in 2026, you need to understand which type of pharmacy they use:
Section 503A pharmacies
- Patient-specific: compounds prescriptions for individual patients
- Cannot compound large batches in advance
- Regulated by state boards of pharmacy
- Operates under Section 503A of FD&C Act
- Status: Continues to operate; not directly affected by shortage list removal
- Limitation: Cannot compound an "essentially a copy" of a commercially available drug without medical necessity
Section 503B outsourcing facilities
- Bulk preparation: can compound large batches for distribution
- Required to follow current Good Manufacturing Practice (cGMP)
- Regulated by the FDA directly
- Operates under Section 503B of FD&C Act
- Status: Significantly restricted after shortage delisting; semaglutide and tirzepatide are not on 503B bulks list
- Limitation: Bulk GLP-1 compounding is now largely prohibited under federal law
In practical terms: most legitimate 2026 telehealth providers operate through 503A pharmacy partnerships, where each patient's prescription is compounded individually based on documented medical necessity. The legal threshold for 503A compounding requires the provider's clinician to determine that the commercially available product (Wegovy, Zepbound, etc.) is unavailable or medically unsuitable for the specific patient.
If a telehealth provider is offering compounded GLP-1s in mass quantities at uniform doses without genuine patient-specific clinical evaluation, they're operating in a legally gray area that the FDA is actively targeting. Compliant providers structure their intake to document patient-specific medical necessity for each prescription — slower and more involved, but operating within the rules.
What "essentially a copy" actually means
The phrase that drives most current FDA enforcement is "essentially a copy" of a commercially available drug. Under both 503A and 503B, federal law prohibits compounding pharmacies from regularly or routinely compounding drugs that are essentially copies of FDA-approved products. The standard exists to prevent compounding from competing with the FDA-approval process.
For GLP-1s specifically, this means a 503A pharmacy generally cannot compound semaglutide or tirzepatide at the exact dose, formulation, and concentration of Wegovy, Ozempic, or Zepbound — because doing so would be making "essentially a copy." What's typically permissible is compounding a different concentration, a different dose tier, or a different formulation (oral tablets, micro-doses, combination products with B12 or other components) that addresses a documented patient-specific clinical need.
This is why most 2026 compounded GLP-1 products from compliant providers come in slightly different concentrations or formats than brand-name Wegovy or Zepbound — the regulatory pathway requires it.
Why prices have stayed competitive despite enforcement
You might expect compounded GLP-1 prices to spike as the regulatory environment tightened. They haven't. Here's why:
- 503A pathway remains open. Patient-specific compounding by state-licensed pharmacies continues largely unaffected by the shortage delisting.
- Active pharmaceutical ingredient (API) supply has stabilized. Earlier supply tightness in 2024 has eased as more API manufacturers have come online.
- Competition between providers. The market has consolidated to ~10–15 major telehealth providers competing aggressively on price, especially for new-customer acquisition.
- Brand-name self-pay is now cheaper. NovoCare and LillyDirect cuts have pulled brand-name prices down to $149–$449/month, putting downward pressure on compounded pricing.
The result: compounded semaglutide pricing in early 2026 sits roughly where it was in late 2024 — $146–$299/month range — even as the regulatory environment has shifted significantly.
Pricing from licensed providers in 2026
Here's what major compliant telehealth providers are charging right now for compounded GLP-1s. All providers below operate through licensed 503A pharmacy partners and structure intake to document patient-specific clinical evaluation:
| Provider | Semaglutide | Tirzepatide | Notable |
|---|---|---|---|
| Yucca Health | $149 / $249 | $258+ | Lowest cash-pay entry |
| Care Bare Rx | $169/mo | — | Wellness-focused care included |
| Novi Weight Loss | $174/mo all-in | — | Includes free coaching |
| MEDVi | $179 / $299 | $279 / $399 | Oral tablet option, LegitScript certified |
| Synergy Rx | $199/mo | $299/mo | Concierge care model |
| Sprout Health | $229/mo | — | Flexible micro-dosing |
Care Bare Rx operates through licensed 503A pharmacy partners with a wellness-led care model — ongoing provider check-ins, structured guidance, and patient-specific clinical evaluation built into the intake. Stable pricing through the 2025–2026 regulatory transition.
Check Care Bare Rx →What could change pricing — or access — in 2026
Three pending developments could shift the compounded GLP-1 market substantially over the next 6–12 months:
1. Further FDA enforcement
The September 2025 warning letters and February 2026 follow-ups suggest the FDA is taking a more active enforcement stance. If the agency moves from warning letters to consent decrees, injunctions, or facility shutdowns, supply could tighten quickly and prices could spike. Patients on compounded plans should have a backup pathway in mind.
2. Brand-name price cuts
Novo Nordisk announced in February 2026 that the list price for Wegovy and Ozempic will drop to roughly $675/month starting January 1, 2027 — about a 50% reduction. Eli Lilly has signaled similar moves. As the brand-name premium shrinks, compounded pricing may face pressure to drop further or risk losing market share.
3. Medicare BALANCE program
Starting July 1, 2026, qualifying Medicare beneficiaries can get Zepbound KwikPen at $50/month copays through the new BALANCE bridge program (running through December 2026). This pulls a large patient cohort out of the cash-pay market and could shift competitive dynamics for compounded providers serving that demographic.
If the regulatory environment continues tightening and you want to lock in FDA-approved access, brand-name GLP-1s through manufacturer self-pay programs are now significantly more affordable than they were in 2024. The Wegovy pill at $149/month is the cheapest FDA-approved entry point. Sesame Care and similar platforms can route you to brand-name pathways if you want to move off compounded entirely.
How to evaluate a compounded GLP-1 provider in 2026
If you're considering compounded treatment, these are the questions worth asking before you enroll:
- Which pharmacy partner do they use? Reputable providers will name their compounding pharmacy and confirm it's licensed in your state. Avoid providers that won't disclose the source.
- Is the pharmacy LegitScript certified? LegitScript certification isn't required by law, but it signals the pharmacy meets transparency and safety standards.
- How does the intake document medical necessity? Compliant 503A compounding requires documented patient-specific clinical evaluation. If the intake feels rubber-stamp, that's a regulatory red flag.
- What's the medication source? The FDA maintains a "green list" of API manufacturers whose facilities meet safety standards. Reputable providers source API from compliant manufacturers.
- How is medication shipped? Compounded GLP-1s require refrigeration. Verify cold-chain shipping and inspect the package on arrival.
- What's the cancellation policy? Avoid providers requiring multi-month upfront payment or charging cancellation fees.
Frequently asked questions
Are compounded semaglutide and tirzepatide still legal in 2026?
Yes, when compounded by a licensed 503A pharmacy for a specific patient based on documented clinical evaluation. Bulk compounding by 503B outsourcing facilities is largely prohibited because semaglutide and tirzepatide are no longer on the FDA drug shortage list.
Why is the FDA sending warning letters to compounders?
Most 2025–2026 warning letters target either marketing claims (calling compounded products "generic" versions, or claiming equivalence to FDA-approved drugs) or quality violations (cGMP noncompliance, insanitary conditions, API sourcing from unregistered facilities). Compliant providers can avoid both categories.
Could my provider lose access to compounded medication?
Possibly. The FDA's enforcement posture has tightened progressively since 2025. If your provider receives a warning letter or their pharmacy partner is shut down, your access could be interrupted. Building a backup plan — knowing which other provider you'd switch to, or which brand-name pathway you'd use — is sensible.
Is compounded medication as effective as brand-name?
Compounded medications use the same active ingredient as brand-name drugs, but they have not been evaluated by the FDA as finished products. Clinical trial data exists for branded semaglutide (STEP trials, ~15% body weight loss) and branded tirzepatide (SURMOUNT trials, ~20–21% body weight loss). Whether compounded versions deliver equivalent outcomes has not been established with the same evidence base.
What about Novo Nordisk and Eli Lilly cease-and-desist letters?
Both manufacturers have been sending cease-and-desist letters to compounders and telehealth platforms throughout late 2025 and 2026. These letters typically demand the recipient stop selling compounded versions and threaten litigation. They've been part of a broader industry push to consolidate the market around brand-name products at lower self-pay prices.
The bottom line
In April 2026, compounded semaglutide and tirzepatide remain available through licensed 503A pharmacies operating under patient-specific compounding rules. Pricing is competitive — $146–$299/month for semaglutide and $258–$399/month for tirzepatide — and meaningfully cheaper than most brand-name pathways. But the regulatory environment is actively tightening, with 50+ FDA warning letters in 2025–2026, manufacturer cease-and-desist letters, and an April 2026 FDA reaffirmation of the "essentially a copy" standard.
For patients prioritizing cost, compounded remains the cheapest path. For patients prioritizing regulatory certainty, the new lower self-pay prices for brand-name Wegovy ($149/month for the pill, $349/month for injection) and Zepbound ($299–$449/month) close enough of the gap that going FDA-approved is more reasonable than it was 18 months ago. Most patients will benefit from understanding both pathways and choosing based on individual priorities rather than defaulting to one.
For live pricing across compounded and brand-name providers, see our main comparison table, updated daily. To model your specific 12-month cost on multiple pathways, use the True Monthly Cost Calculator.